Sensei Biotherapeutics Inc (SNSE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sensei Biotherapeutics Inc (SNSE) has a cash flow conversion efficiency ratio of -0.056x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.73 Million) by net assets ($191.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Sensei Biotherapeutics Inc (SNSE) net asset quality to measure how much of total assets are equity-financed.
Sensei Biotherapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Sensei Biotherapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore SNSE debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Sensei Biotherapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sensei Biotherapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Predictive Oncology Inc
NASDAQ:POAI
|
0.021x |
|
Devonian Health Group Inc
V:GSD
|
-0.675x |
|
Stern Groep N.V.
AS:PBH
|
0.907x |
|
Ortivus AB ser. B
ST:ORTI-B
|
-0.529x |
|
Drillcon AB
ST:DRIL
|
0.073x |
|
Prostar Holdings Inc
V:MAPS
|
-0.535x |
|
TAG Oil Ltd.
V:TAO
|
-0.021x |
|
Foxx Development Holdings Inc.
NASDAQ:FOXX
|
-0.024x |
Annual Cash Flow Conversion Efficiency for Sensei Biotherapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Sensei Biotherapeutics Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Sensei Biotherapeutics Inc (SNSE) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $18.59 Million | $-20.45 Million | -1.100x | -71.17% |
| 2024-12-31 | $38.39 Million | $-24.67 Million | -0.643x | -30.24% |
| 2023-12-31 | $64.89 Million | $-32.02 Million | -0.493x | -30.75% |
| 2022-12-31 | $103.41 Million | $-39.03 Million | -0.377x | -82.74% |
| 2021-12-31 | $146.51 Million | $-30.26 Million | -0.207x | +81.46% |
| 2020-12-31 | $15.89 Million | $-17.70 Million | -1.114x | -992.43% |
| 2019-12-31 | $-68.66 Million | $-8.57 Million | 0.125x | -35.27% |
| 2018-12-31 | $-53.48 Million | $-10.31 Million | 0.193x | -- |
About Sensei Biotherapeutics Inc
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune … Read more